Abstract:Background: During tumor growth, tumor cells interact with their tumor microenvironment (TME) resulting in the development of heterogeneous tumors that promote tumor occurrence and progression. Recently, there has been extensive attention on TME as a possible therapeutic target for cancers. However, an accurate TME-related prediction model is urgently needed to aid in the assessment of patients' prognoses and therapeutic value, and to assist in clinical decision-making. As such, this study aimed to develop and validate a new prognostic model based on TME-associated genes for BC patients. Methods: Transcriptome data and clinical information for BC patients were extracted from The Cancer Genome Atlas (TCGA) database. Gene Expression Omnibus (GEO) and IMvigor210 databases, along with the MSigDB, were utilized to identify genes associated with TMEs (TMRGs). A consensus clustering approach was used to identify molecular clusters associated with TMEs. LASSO Cox regression analysis was conducted to establish a prognostic TMRG-related signature, with verifications being successfully conducted internally and externally. Gene ontology (GO), KEGG, and single-sample gene set enrichment analyses (ssGSEA) were performed to investigate the underlying mechanisms. The potential response to ICB therapy was estimated using the Tumor Immune Dysfunction and Exclusion (TIDE) algorithm and Immunophenoscore (IPS). Additionally, it was found that the expression level of certain genes in the model was significantly correlated with objective responses to anti-PD-1 or anti-PD-L1 treatment in the IMvigor210, GSE111636, GSE176307, or Truce01 (registration number NCT04730219) cohorts. Finally, real-time PCR validation was performed on 10 paired tissue samples, and in vitro cytological experiments were also conducted on BC cell lines. Results: In BC patients, 133 genes differentially expressed that were associated with prognosis in TME. Consensus clustering analysis revealed three distinct clinicopathological characteristics and survival outcomes. A novel prognostic model based on nine TMRGs (including C3orf62, DPYSL2, GZMA, SERPINB3, RHCG, PTPRR, STMN3, TMPRSS4, COMP) was identified, and a TMEscore for OS prediction was constructed, with its reliable predictive performance in BC patients being validated. MultiCox analysis showed that the risk score was an independent prognostic factor. A nomogram was developed to facilitate the clinical viability of TMEscore. Based on GO and KEGG enrichment analyses, biological processes related to ECM and collagen binding were significantly enriched among high-risk individuals. In addition, the low-risk group, characterized by a higher number of infiltrating CD8+ T cells and a lower burden of tumor mutations, demonstrated a longer survival time. Our study also found that TMEscore correlated with drug susceptibility, immune cell infiltration, and the prediction of immunotherapy efficacy. Lastly, we identified SERPINB3 as significantly promoting BC cells migration and invasion through differential expression validation and in vitro phenotypic experiments. Conclusion: Our study developed a prognostic model based on nine TMRGs that accurately and stably predicted survival, guiding individual treatment for patients with BC, and providing new therapeutic strategies for the disease.

Multi-omics Analysis of Tumor Mutational Burden Combined with Prognostic Assessment in Epithelial Ovarian Cancer Based on TCGA Database.

Development and Validation of a Tumor Mutation Burden-Related Immune Prognostic Signature for Ovarian Cancers

Significance of tumor mutation burden combined with immune infiltrates in the progression and prognosis of ovarian cancer

Association between tumor mutation burden and immune infiltration in ovarian cancer

A novel tumor mutational burden-based risk model predicts prognosis and correlates with immune infiltration in ovarian cancer

CXCL13, FCRLA, PLA2G2D and MS4A1 Were Identified As Prognostic Biomarkers and Correlated with Immune Infiltration in Ovarian Cancer by Integrating TMB and Microenvironment Analysis

Analysis of tumor mutation burden combined with immune infiltrates in endometrial cancer

Identification of a prognostic signature of epithelial ovarian cancer based on tumor immune microenvironment exploration

Integrative analysis from multi‐center studies identifies a weighted gene co‐expression network analysis‐based Tregs signature in ovarian cancer

Identification of tumor mutation burden-associated molecular and clinical features in cancer by analyzing multi-omics data

Integrating the genomic and TCR repertoire signatures predicts prognosis in primary epithelial ovarian cancer.

The gene signature of tertiary lymphoid structures within ovarian cancer predicts the prognosis and immunotherapy benefit

Integrated analysis of prognostic immune-related genes in the tumor microenvironment of ovarian cancer

Establishment of an ovarian cancer exhausted CD8+T cells-related genes model by integrated analysis of scRNA-seq and bulk RNA-seq

Multiomics Analysis of Tumor Mutational Burden Across Cancer Types

Improving ovarian cancer treatment decision using a novel risk predictive tool

Association of High Tumor Mutation (TMB) with DNA Damage Repair (DDR) Alterations and Better Prognosis in Ovarian Cancer.

Tumor mutation burden in connection with immune-related survival in uterine corpus endometrial carcinoma

Prognostic and immunotherapeutic potential of regulatory T cell‐associated signature in ovarian cancer

Identification and validation of a dysregulated TME-related gene signature for predicting prognosis, and immunological properties in bladder cancer

Exploring tumor microenvironment in molecular subtyping and prognostic signatures in ovarian cancer and identification of SH2D1A as a key regulator of ovarian cancer carcinogenesis